Related Experiment Video
Updated: Sep 27, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Up-regulation of MDR1 function and expression by cisplatin in LLC-PK1 cells
Kohji Takara1, Masayuki Tsujimoto, Misato Kokufu
1Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto, Japan. takara@mb.kyoto-phu.ac.jp
Abstract:
To examine whether cisplatin affects the multidrug transporter MDR1/P-glycoprotein in the kidneys, the effects of cisplatin on cell sensitivity to an anticancer drug, MDR1 function and expression were examined by assessing the growth inhibition by the MDR1 substrate paclitaxel, the uptake and efflux of the MDR1 substrate Rhodamine123 and the level of MDR1 mRNA, respectively. Porcine kidney epithelial LLC-PK1 cells were used, as they have a structure and function similar to those of renal proximal tubular cells and physiologically express low levels of MDR1. The growth inhibitory curve of LLC-PK1 cells by paclitaxel was shifted to a higher concentration range by pretreatment with 1 micro M cisplatin for 48 h. The uptake and efflux of Rhodamine123 were significantly reduced and enhanced, respectively, by pretreatment with 1 micro M cisplatin for 48 h. This enhanced efflux was suppressed by the representative MDR1 substrate/inhibitor ciclosporin. The expression of MDR1 mRNA was increased by the existence of cisplatin for 48 h. These observations taken together suggested that the transient exposure to cisplatin could cause the up-regulation of MDR1 in LLC-PK1 cells.
Insights
Cisplatin treatment increases multidrug resistance 1 (MDR1) expression and function in kidney cells. This suggests transient cisplatin exposure can up-regulate MDR1, potentially affecting drug efficacy.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Background:
- The multidrug transporter MDR1/P-glycoprotein plays a crucial role in drug efflux from cells.
- Understanding how chemotherapy agents like cisplatin interact with MDR1 in renal cells is vital for optimizing treatment outcomes.
Purpose of the Study:
- To investigate the impact of cisplatin on the function and expression of MDR1 in kidney epithelial cells.
- To determine if cisplatin exposure alters cellular sensitivity to MDR1 substrates.
Main Methods:
- Utilized porcine kidney LLC-PK1 cells, which mimic renal proximal tubular cells.
- Assessed cell sensitivity to paclitaxel, Rhodamine123 uptake/efflux, and MDR1 mRNA levels after cisplatin pretreatment.
- Evaluated the effect of ciclosporin on Rhodamine123 efflux.
Main Results:
- Cisplatin pretreatment shifted the paclitaxel growth inhibitory curve to higher concentrations.
- Rhodamine123 uptake decreased, while efflux significantly increased post-cisplatin exposure.
- Ciclosporin treatment reversed the enhanced Rhodamine123 efflux, confirming MDR1 involvement.
- MDR1 mRNA expression levels were elevated by cisplatin exposure.
Conclusions:
- Transient exposure to cisplatin leads to the up-regulation of MDR1 in LLC-PK1 cells.
- Cisplatin's effect on MDR1 may influence the transport of other drugs within the kidneys.
- Further research is warranted to explore the clinical implications of cisplatin-induced MDR1 modulation in renal drug transport.
Related Concept Videos
Abnormal Proliferation
Treatment Resistant Cancers
Master Transcription Regulators
